Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
153
resultados
Última actualización
04/05/2025 [07:29:00]
Resultados 125 a 150 de 153
Resumen de: US2025082721A1
A method for ameliorating or treating Parkinson's disease includes administering a composition including an osmotin protein as effective component to a subject in need thereof. The composition has the effects of alleviating behavior and motor skill deficits induced by MPTP/α-synuclein, protecting dopaminergic neurons, regulating the expression level of neuroinflammation-related proteins, inhibiting apoptotic cell death induced by MPTP/α-synuclein, alleviating cell damage caused by overexpression of α-synuclein (A53T), reducing the accumulation of α-synuclein caused by activation of AMPK and subsequent autophagy, regulating the dendritic complex structure, increasing the spine density in pyramidal neurons, alleviating the cognitive deficits, and restoring the expression of synaptic markers. The osmotin protein can be advantageously used for a functional health food or a pharmaceutical product for preventing, ameliorating, or treating Parkinson's disease.
Resumen de: WO2025050785A1
The present invention relates to a TPK expression virus capable of being administered through intravenous injection. The TPK expression virus is AAV-TPK, and a genome thereof comprises a neuron-specific promoter, a nucleotide sequence for coding TPK, and a WPRE. Also provided are an AAV-TPK construction method and a use thereof in the preparation of a drug for preventing or treating Alzheimer's disease. The AAV-TPK is serotype rAAV-CAP-B10. In clinical application, the AAV-TPK can be administrated through direction injection across a blood-brain barrier, or is administrated through peripheral intravenous injection, and is used for treating or preventing Alzheimer's disease.
Resumen de: WO2025051214A1
Provided are a compound having a new structure and serving as an LRRK2 inhibitor, and a stereoisomer, optical isomer, and pharmaceutically acceptable salt thereof. A new direction is provided for the development of LRRK2 inhibitor drugs. In vitro enzyme and cell activity inhibition studies show that these compounds all have a strong inhibitory effect, and can be used as promising compounds for treating and/or preventing LRRK2-mediated diseases (such as neurodegenerative diseases, especially Parkinson's disease).
Resumen de: WO2025051280A1
The present invention belongs to the field of traditional Chinese medicine, and specifically relates to the use of a traditional Chinese medicine composition in the preparation of a pharmaceutical for preventing or/and treating amyotrophic lateral sclerosis. Specifically, the traditional Chinese medicine composition is prepared from herba schizonepetae, radix saposhnikoviae divaricatae, rhizoma seu radix notopterygii, radix angelicae pubescentis, radix bupleuri, radix peucedani, rhizoma chuanxiong, fructus aurantii, poria cocos, radix platycodi, and radix glycyrrhizae. Pharmacodynamic test results show that the traditional Chinese medicine composition provided by the present invention can prolong survival, maintain weight increase, and increase the limb strength of amyotrophic lateral sclerosis mouse models, has the effects of delaying the progression of muscle atrophy and delaying motor neuron apoptosis, and has a precise therapeutic effect for treating amyotrophic lateral sclerosis.
Resumen de: WO2025052177A2
The subject invention pertains to compositions and methods to inhibit the interaction between two protein molecules, PTEN and PSD-95, in neurons. The inhibition of the interaction between PTEN and PSD-95 is used in methods of treating Alzheimer's disease. The compositions comprise isochlorogenic acid B, isochlorogenic acid C, and amaranth.
Resumen de: WO2025053994A1
Described herein are compounds that increase levels of sCLU (clusterin secreted isoform) and associated methods of treating Alzheimer's disease, diabetes and cardiovascular disease.
Resumen de: WO2025053670A1
The present invention relates to a vanillic acid derivative compound, which can be formed by a dehydration condensation reaction between vanillic acid and catecholamine. The vanillic acid derivative compound according to the present invention can be used as a therapeutic agent for Alzheimer's disease and neuroinflammation. In addition, the present invention relates to a composition for treating Alzheimer's disease and a composition for treating neuroinflammation, the compositions comprising the compound.
Resumen de: AU2023320561A1
Embodiments of the disclosure include methods and compositions related to use of compound comprising a particular peptide linked to a dye. In specific embodiments, the peptide DIRG is linked to the BODIPY dye. In specific embodiments, the compositions are utilized for treatment of neurological conditions and secondary pathologies related therewith, such as spinal cord injury and Alzheimer's Disease, as examples.
Resumen de: AU2023265569A1
The present disclosure relates to the c-Abl inhibitor vodobatinib, or a pharmaceutically acceptable salt thereof, for use in treating, delaying, inhibiting, or suppressing the progression of neurodegenerative diseases, preferably early stage Parkinson's disease, in a subject.
Resumen de: EP4520757A1
The present disclosure relates to an isobenzofuran-1(3H)-one derivative, which is a kinase inhibitor, and a use thereof and, more specifically, to an isobenzofuran-1(3H)-one derivative having HPK1 inhibitory activity and MLK3 inhibitory activity and a pharmaceutical composition containing same for preventing or treating cancer, virus infectious diseases, Parkinson's disease, non-alcoholic steatohepatitis, or tuberculosis. In addition, the compound can be advantageously used as a composition for prevention or treatment of cancer as it is administered in combination with an anticancer agent or a cell therapy product.
Resumen de: MX2024014831A
Compound of Formula (I)-(V), compositions comprising at least one compound chosen from compounds of Formula (I)-(V), and methods of using the same, including in treatment of Alzheimer's disease.
Resumen de: US2025074973A1
The present disclosure relates generally to methods of treating Huntington's disease in a subject in need thereof. The method comprises determining that the subject has an elevated level of C4a or an elevated C4a/C4 ratio; and administering to the subject an inhibitor of the classical complement pathway.
Resumen de: US2025074902A1
Provided are a fused bicyclic heteroaryl amide compound as a protein aggregation inhibitor, as well as the use of such compound in the treatment or prevention of neurodegenerative diseases characterized by protein aggregation, such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, dementia with Lewy bodies, Parkinson's disease dementia, multiple system atrophy, amyotrophic lateral sclerosis, Huntington's disease, and cancer.
Resumen de: US2025074951A1
The present invention relates to the discovery of compositions and methods for altering Amyloid Precursor Protein (APP) processing. Alerting APP processing is aids the treatment of neuropathological disorders such as those associated with HIV infection and Alzheimer's disease (AD). The invention includes fusion protein constructs that include an effector protein and an HSV US9 protein or functionally active fragment thereof that reduce the amount of amyloid □-protein produced in a cell.
Resumen de: WO2025049807A1
Disclosed are novel strategies for the treatment of patients with Parkinson's disease and other secondary Parkinsonian disorders. Disclosed are DA neuronal cells that have been modified in vitro with a genetic insertion of GDNF. The GDNF coding sequence is inserted under the transcriptional control of a promotor such that secreted proteins are made and taken up by the endogenous cells after the administered engineered cells have matured to a Neuronal Mature Cell Type to promote survival of endogenous neurons. Also disclosed are DA neuronal cells that have been modified with a genetic insertion of GBA in vitro and are hemizygous null for SNCA. The GBA coding sequence is inserted under the transcriptional control of a ubiquitous promotor and the secreted proteins are made and taken up by the graft and endogenous cells immediately upon transplantation to promote long-term graft integrity.
Resumen de: WO2025045033A1
Provided are a gene therapy vector for treating Parkinson's disease and a use thereof. Specifically, provided is an adeno-associated virus (AAV) vector for treating Parkinson's disease, which can simultaneously express functional tyrosine hydroxylase (TH), GTP-cyclohydrolase 1 (GCH1) and aromatic amino acid decarboxylase (AADC) to promote dopamine synthesis. Also provided are an AAV virus particle containing the AAV vector, a composition containing the AAV vector or the AAV virus particle, and uses of the AAV vector, the AAV virus particle and the composition in the preparation of drugs for preventing or treating Parkinson's disease.
Resumen de: WO2025048759A1
The present invention pertains to benzimidazole derivatives of formula (I) and their inhibitory activity against mPGES-1. It also encompasses pharmaceutical compositions that include these benzimidazole derivatives and their application in treating mPGES-1-mediated diseases. The purpose of this invention is to create novel compounds that inhibit inducible mPGES-1, an enzyme responsible for catalyzing the final step in the biosynthesis of PGE2 from AA. These compounds are intended for the treatment of various inflammatory conditions, including but not limited to Parkinson's disease, autoimmune diseases, allergic disorders, rhinitis, coronary heart disease, ulcers, osteoarthritis, rheumatoid arthritis, systemic sclerosis, periodontitis, colon cancer, inflammatory bowel disease, cutaneous sclerosis, neuropathic pain, inflammation, pain, fever, migraine, chronic pain, acute pain, headache, asthma, pulmonary fibrosis, fibromyalgia, dysmenorrhea, atherosclerosis, gout, arthritis, rheumatic fever, multiple sclerosis, Hodgkin's disease.
Resumen de: WO2025048007A1
The present invention relates to use of a novel compound for preventing, alleviating or treating Alzheimer's disease, and the novel compound exhibits an inhibitory effect on tau protein aggregation. In addition, it was identified that presenilin 1 was reduced by treatment using the novel compound. Therefore, the novel compound can be effectively used in the development of a therapeutic agent for Alzheimer's disease.
Resumen de: WO2025048409A1
The compound represented by chemical formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, according to one aspect, can be used as a prophylactic or therapeutic agent for degenerative diseases such as age-related macular degeneration (AMD) in which lack of HTRA1 activity is a factor in worsening the disease, cerebral amyloid angiopathy, hereditary stroke (CADASIL), and Alzheimer's disease (AD), and can be used as an adjuvant for efficiently and accurately screening an HTRA activity modulator without a change in temperature or addition of a substrate.
Resumen de: US2025073341A1
The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
Resumen de: WO2025044931A1
Provided is an antibody that binds to β-amyloid (Aβ), or an antigen-binding fragment thereof. Further provided are a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a cell comprising the antibody or the antigen-binding fragment or nucleic acid thereof, a pharmaceutical composition, a kit, and the use of the antibody or the antigen-binding fragment thereof in the preparation of a drug used for treating or preventing a disease caused by abnormal accumulation or deposition of Aβ in subjects.
Resumen de: AU2023326620A1
A method of treating Parkinson's disease in a patient who is receiving N doses of levodopa per day to provide a total daily dose of X mg of levodopa and who is starting to experience motor fluctuations or starting to show signs of "wearing-off", the treatment comprising administering more than N doses of levodopa per day to provide a total daily dose of X mg of levodopa and administering a single daily dose of Y mg of opicapone, wherein X is from 100 to 1000, N is from 2 to 10 and Y is from 25 to 50.
Resumen de: AU2023312980A1
The present disclosure provides methods, compositions and kits for prophylactic treating or preventing a degenerative disease related to amyloid. The compositions and kits comprise Sigma-1 receptor agonist, an allosteric sigma agonist, and/or a dual agonist of Sigma-1 and M1. The compositions and kits elicit effects of delaying the onset, deterring the progress, and/or diminish the likelihood of the degenerative disease, such as deterring the memory loss and/or cognition decline in Alzheimer's disease.
Resumen de: WO2025049979A1
Disclosed herein are peptides or peptoids including from 8 to 20 amino acids, including a plurality of hydrophobic amino acids and a plurality of charged amino acids, wherein spacing of the plurality of hydrophobic amino acids and the plurality of charged amino acids aligns with the spacing of hydrophobic amino acids and oppositely charged amino acids in an ApoE protein or polypeptide. Also disclosed are pharmaceutical compositions that include a peptide or peptoid as disclosed, as well as various methods of using the peptides or peptoids, and such pharmaceutical compositions. These methods include blocking Aβ/ApoE interaction, inhibiting Aβ protein oligomerization, and inhibiting amyloid plaque and/or tau aggregate formation, as well as the treatment of Alzheimer's Disease and other tauopathies.
Nº publicación: WO2025049336A2 06/03/2025
Solicitante:
BLUEROCK THERAPEUTICS LP [US]
BLUEROCK THERAPEUTICS LP
Resumen de: WO2025049336A2
This disclosure relates to methods and compositions for the treatment of Parkinson's disease, a neurodegenerative disorder characterized by a loss of dopaminergic neurons. In particular, this disclosure provides formulations of dopaminergic cells demonstrated to possess a therapeutic impact on both motor and non-motor symptoms of the disease.
BOPI
Sede Electrónica
